Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00439257 · ClinicalTrials.gov registry record

Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)

A clinical trial, sponsored by US Department of Veterans Affairs.

Completed
Registry status
124
Enrollment target

NCT00439257: Completed study, sponsored by US Department of Veterans Affairs.

NCT00439257 is a clinical trial that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 124 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00439257 has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
124 participants
Enrollment target

Study Summary

The treatment of multiple sclerosis was evolving in light of specific drug therapies to treat the disease, refinements and acceptance of imaging with MRI to diagnose and monitor the disease process, and progress in understanding the pathogenesis of the inflammatory demyelinating process. The result was to raise new issues in the treatment of the disease, which are then being addressed by studies, including when to initiate treatment and the treatment of partial responders to existing therapies. Paralleling strides in treatment, and of particular importance to the Veterans Administration, was the effectiveness of such therapies, both in terms of cost to the VA Health Care System and quality of life of veterans with multiple sclerosis. This study addressed these issues.

Trial Details

FieldValue
Enrollment Target 124 participants
Est. Completion 2000-06
US Department of Veterans Affairs

632 total trials

What the finished NCT00439257 record still lists

NCT00439257 is an observational study that tracks outcomes without assigning an intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00439257 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00439257 about?

NCT00439257 is a clinical study titled "Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)". The treatment of multiple sclerosis was evolving in light of specific drug therapies to treat the disease, refinements and acceptance of imaging with MRI to diagnose and monitor the disease process, and progress in understanding the pathogenesis of the inflammatory demyelinating process. The result ...

What is the current status of trial NCT00439257?

This trial is currently completed. The enrollment target is 124 participants. Estimated completion is 2000-06.

Who is sponsoring clinical trial NCT00439257?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523014 · 124 participants · Phase 2

    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

  • NCT02670707 · 124 participants · Phase 3

    Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

  • NCT02830724 · 124 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • NCT04748809 · 124 participants · NA

    Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

Source: ClinicalTrials.gov NCT00439257, the US trial registry maintained by the National Library of Medicine. NCT00439257 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.